Drugs.com - Clinical Trials

Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrated A1C Reduction and a Safety Profile Consistent with Daily Insulin in Multiple Phase 3 Trials

INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin...

Jun 23, 2025 - 00:20
 0
Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrated A1C Reduction and a Safety Profile Consistent with Daily Insulin in Multiple Phase 3 Trials
INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin...
Read More

Tags:

Previous Article

Novo Nordisk's Mim8 Prophylaxis Treatment Shown to be Well-Tolerated When Switch...

Next Article

Lilly's Oral GLP-1, Orforglipron, Showed Compelling Efficacy and a Safety Profil...

Related Posts

Repurposing Blood Pressure Drug Reserpine May Prevent Vision Loss in Inherited Blinding Diseases

Repurposing Blood Pressure Drug Reserpine May Prevent V...

May 12, 2025  0

Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC

Johnson & Johnson’s TAR-200 Monotherapy Achieves High D...

May 12, 2025  0

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Receives U.S. FDA Fast Track Designa...

May 12, 2025  0